Institutional changes of China's drug regulation and improvement solutions

doi:10.5246/jcps.2015.12.105

Journal of Chinese Pharmaceutical Sciences ›› 2015, Vol. 24 ›› Issue (12): 821-825.DOI: 10.5246/jcps.2015.12.105

• Drug administration column • Previous Articles Next Articles

Institutional changes of China's drug regulation and improvement solutions

Lujia Chen¹, Guozhen Liu², Guo Huang³, Dongsheng Yang^4*, Bin Jiang^1*

1. Department of Administrative and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
2. Institute for Medical Humanities, Peking University Health Science Center, Beijing 100191, China
3. China Food and Drug Administration, Beijing 100053, China
4. R&D-based Pharmaceutical Association Committee, Beijing 100004, China

Received:2015-06-24 Revised:2015-07-14 Online:2015-12-22 Published:2015-09-10
Contact: Tel.: 13601100121, E-mail: binjiang@bjmu.edu.cn
Supported by:
National Social Science Fund (Grant No. 13BGL141).

Abstract

Abstract:

Drug regulation is the most important policy to ensure drug safety. In this article, we analyzed institutional changes and problems in China’s drug regulation. In addition, suggestions were provided to enhance the capacity of drug regulation, including a clearer functional positioning for drug regulation, increased resource inputs in drug regulation at central level, a more rational allocation of vertical drug regulatory functions, and an improved supervision mechanism for regulatory departments.

Key words: Drug regulation, Institutional change, Vertical allocation

CLC Number:

R951

Supporting:

Lujia Chen, Guozhen Liu, Guo Huang, Dongsheng Yang, Bin Jiang. Institutional changes of China's drug regulation and improvement solutions[J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(12): 821-825.

[1]	Chengxin Xie, Wei Wang, Ge Huang, Xin Jin, Chenglong Wang, Dong Yin. Pharmacist-led interventions to reduce inappropriate drug use in the orthopaedics department in China [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(6): 375-382.
[2]	Yuyao Nie, He Wang, Linguang Zhou, Luwen Shi, Bin Jiang. Pharmacists’ perceptions of generic drugs in China [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(5): 364-368.
[3]	Zhifeng Nie, Chunxia Man, Xin Yi, Yi Liu, Zhigang Guo, Xiaodong Guan, Luwen Shi. Impact of the zero-markup drug policy on volume of medical service: based on 57 county hospitals of China [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(3): 220-226.
[4]	Ruojing Zhou, Bin Jiang. Effects of drug purchasing under joint price caps policy in Fujian Province, China [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(2): 139-152.
[5]	Dongsheng Yang, Lingyun Ma, Jianzhao Niu, Mingdi Xu. Brief introduction for application of USA authorized generic drugs [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(6): 439-445.
[6]	Dongsheng Yang, Lingyun Ma, Jianzhao Niu, Mingdi Xu. Brief introduction for application of the USA national drug code [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(3): 203-208.
[7]	Ting Yin, Bin Jiang. Effects of drug procurement under cap price policy in Sanming [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(11): 799-804.
[8]	Jianzhao Niu, Dongsheng Yang, Mingdi Xu. Brief introduction for search and determination of the comparator product for generic medicinal product application in the EU [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(11): 805-812.
[9]	Shuyun Feng, Jinhui Guo, Yizhong Lu. Pharmaceutical practice and value of pharmacists under the new medical reform situation [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(9): 630-636.
[10]	Mengyuan Que, Ting Yin, Xiaoping Li, Bin Jiang. Status quo of resource allocation of Chinese grass-roots food and drug administrations: from 2011 to 2016 [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(9): 637-643.
[11]	Shuai Wang, Ting Yin, Ningtai Luo, Xiaoping Liu, Bin Jiang. Research on the sharing mechanism of drug price information in China- from the perspective of intergovernmental information sharing [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(8): 582-587.
[12]	Xiao Chen, Xiang Gao, Jie Chen, Sheryl L Chow, Moses S.S. Chow. New direction for clinical pharmacy in China: adopting a “form follows function” approach to improve future healthcare outcomes [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(5): 352-360.
[13]	Mengyuan Fu, Xiaodong Guan, Guoxu Wei, Xiaoxiong Xin, Luwen Shi. Medical service utilisation, economic burden and health status of patients with rare diseases in China [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(5): 361-369.
[14]	Xianghong Lin, Hao Hu, Yi Liu, Xiaodong Guan, Jiafang Song, Luwen Shi. The comprehensive influence of firm-level factors on drug product internationalization of Chinese pharmaceutical firms [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(3): 209-214.
[15]	Zhiyan Liu, Xiaoyan Nie, Qian Xiang, Luwen Shi, Yimin Cui. Investigations and feedback on the training mode of professional master’s degree of clinical pharmacy in Peking University and the preliminary exploration of Pharm. D. Education [J]. Journal of Chinese Pharmaceutical Sciences, 2018, 27(2): 131-137.

Institutional changes of China's drug regulation and improvement solutions

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments